Sector News

Major policy shift on costs and safety views as China moves to lift price controls on drugs

March 5, 2015
Life sciences
China Premier Li Keqiang said the government will lift price controls on pharmaceuticals, which would mark a dramatic change of tack in efforts to both widen access to medicines from the cities into the countryside while keeping spending in check.
 
Li announced the decision in his annual government work report plan that opens the annual two-week National People’s Conference, a legislative body that nominally advises the Communist Party-run government on broad policy aims.
 
The report did not disclose details or a timeline. The disclosure is part of a broad statement on China’s intention to eventually lift price controls and give market forces a greater role in its economy.
 
“In principle, we will lift pricing controls over all goods and services that can viably compete in markets,” it said. “The government will stop setting prices for most pharmaceuticals and delegate to lower-level governments the power to set prices for certain basic public services.”
 
China wants to develop the domestic pharmaceutical industry through stronger regulatory measures and has moved in the past two years of the government of Xi Jinping to form a China FDA based on a U.S. model that has issued mandatory requirements to be certified in good manufacturing practices and similar rules aimed at overcoming widespread public concern, and anger, about product safety.
 
At the same time however, the government also aims to control drug spending through price caps and profit-margin regulations to guarantee access even for poor patients, distorting market incentives that some analysts say lead to safety lapses and inappropriate prescriptions.
 
Pharmaceuticals account for about half of total health spending in China, representing 43% of spending per inpatient episode and 51% of spending per outpatient visit, according to government figures.
 
Analysts also say the move is part of a broader drug reform in which the government plans to sell drugs online, shaking up the procurement system entirely and creating a more transparent system.
 
The aim is to solve problems that have plagued hospital pharmacies. Drug sales make up more than 80% of hospital revenue, according to consulting firm Bain & Co.
 
By EJ Lane
 

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach